Newborn bloodspot screening (NBS) began in the early 1960s based on the work of Dr.
Robert “Bob” Guthrie in Buffalo, NY, USA. His development of a screening test for …

Neonatal bloodspot screening (NBS) aims to detect treatable disorders in newborns. The
number of conditions included in the screening is expanding through technological and …

Neonatal bloodspot screening (NBS) programmes that screen for rare but serious conditions
are expanding worldwide. Fast developments for testing and treatment put pressure on …

Newborn bloodspot screening (NBS) policy is a contentious area in Europe. Variation in the
screening panels on offer, in the approach to evidence assessment and in the use of health …

The International Journal of Neonatal Screening (IJNS), founded in 2015 by the International
Society for Neonatal Screening (ISNS), has quickly become the most important journal for …

Newborn screening (NBS) is a public health service that is used to screen for treatable
conditions in many countries, including Thailand. Several reports have revealed low levels …

Population-based newborn bloodspot screening (NBS) targets treatable conditions that are
life-threatening or may cause irreversible damage if treatment is postponed until a diagnosis …

Purpose Newborn bloodspot screening (NBS) programs have expanded significantly in the
past years and are expected to expand further with the emergence of genetic technologies …

Newborn bloodspot screening has been operating successfully in Australia for almost 50
years. Recently, the development of new technologies and treatments has led to calls for the …

Bloodspot screening in newborns is an exemplary public health intervention as it is essential
secondary prevention with proven efficacy and benefit for the early diagnosis and prompt …